← All trials
NCT05330273
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2022
- Primary completion
- Nov 22, 2022
- Completion date
- Nov 22, 2022
- First posted
- Apr 15, 2022
- Last posted
- Nov 4, 2022
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovartisLead sponsor
- Medicines for Malaria VentureCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.